Continuing discussion on bispecific antibodies, attention turns to talquetamab and the MonumenTAL-1 clinical trial for patients with relapsed/refractory multiple myeloma.
Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma
Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma
A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
ASCT Shows No Significant MRD Difference vs Isa-KRd in Multiple Myeloma
Longer follow-up from the phase 3 MIDAS trial may be necessary to evaluate progression-free survival and overall survival.
Busulfan-Enhanced VRd Regimen Improves Efficacy in NDMM
Busulfan/melphalan elicited higher PFS among patients with ISS stage II or stage III disease, and melphalan-200 improved PFS in ISS stage I disease.